Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01297244 · ClinicalTrials.gov registry record · Phase 2
A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma
A Phase 2 study, sponsored by AVEO Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
NCT01297244 is a Phase 2 study that has completed, run by AVEO Pharmaceuticals. The registered enrollment target is 105 participants.
The verdict
NCT01297244, a Phase 2 study, has completed, sponsored by AVEO Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
Study Summary
This is an open-label, single arm, multicenter study. Subjects will be stratified by histology (clear cell versus non-clear cell). Enrollment of non-clear cell subjects will be limited to ≤ 30% of the entire study population.
Interventions
- DRUG Tivozanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2011-01 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01297244
The ClinicalTrials.gov registry entry for NCT01297244 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AVEO Pharmaceuticals, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tivozanib is the first listed.
NCT01297244 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01297244 about?
NCT01297244 is a clinical study titled "A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma". This is an open-label, single arm, multicenter study. Subjects will be stratified by histology (clear cell versus non-clear cell). Enrollment of non-clear cell subjects will be limited to ≤ 30% of the entire study population.
What is the current status of trial NCT01297244?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2011-01. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01297244?
The interventions under investigation include: Tivozanib (DRUG).
Who is sponsoring clinical trial NCT01297244?
This trial is sponsored by AVEO Pharmaceuticals, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.